December 5, 2006 -- Acomplia, the Sanofi-Aventis weight-loss drug, produced impressive results in treating type 2 diabetes; Merck found Janumet effective among type 2 diabetics; Somaxon said nalmefene hydrochloride failed a trial for compulsive gambling; Dynavax will begin a Phase I test of its TLR9 agonist for colorectal cancer; Inspire initiated a Phase II trial of epinastine nasal spray to treat rhinitis; Isis began clinical development of a drug coming from its collaboration with Merck; Sepracor showed Lunestra lowered symptoms of Generalized Anxiety Disorder; Lexicon Genetics wants to begin human testing of a drug for irritable bowel syndrome; and naltrexone from Alkermes blocked an opioid response in patients for 28 days. The Centient Biotech 200™ rose 13 points to end the session at 3996, an increase of .32%. More details...
